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Abstract
White matter damage is a clinically important part of stroke. However, compared to the
mechanisms of neuronal injury in gray matter, white matter pathophysiology remains relatively
understudied and poorly understood. This mini-review aims at summarizing current knowledge on
experimental systems for analyzing the role of white matter injury relevant to stroke. In vitro
platforms comprise primary cultures of both mature oligodendrocytes (OLGs) as well as
oligodendrocyte precursor cells (OPCs). Tissue platforms involve preparations of optic nerve
systems. Whole-animal platforms comprise in vivo models of cerebral ischemia that attempt to
target white matter brain areas. While there is no single perfect model system, the collection of
these experimental approaches have recently allowed a better understanding of the molecular and
cellular pathways underlying OLG/OPC damage and demyelination. A systematic utilization of
these cell, tissue and whole-animal platforms may eventually lead us to discover new targets for
treating white matter injury in stroke and other CNS disorders.
Introduction
Over the past decade, impressive advances have been
made in understanding the basic molecular mechanisms
underlying neuronal death. However, clinically effective
neuroprotectants have not yet been discovered. This has
been especially true in stroke, where many drugs targeting
excitotoxicity, oxidative stress, and inflammation have all
failed [1-3]. Although there are many difficult reasons for
these translational problems [4-6], one potential issue
worth examining further is the lack of emphasis on white
matter.
In the CNS, white matter is primarily comprised of axonal
bundles ensheathed with myelin. The cells forming these
sheaths are the oligodendrocytes (OLGs), which tend to
be arranged in rows parallel to axonal tracts. Just before
and after birth, oligodendrocyte precursor cells (OPCs)
multiply rapidly, mature into OLGs, and develop proc-
esses, which are then involved in the formation of myelin.
Damage to OPCs and OLGs causes loss of myelin synthe-
sis and interruption of proper axonal function. Hence,
even if we protect neurons in gray matter, loss of myelin
and axonal integrity would interfere with neuronal con-
nectivity and function. Neuroprotection cannot be truly
attained without oligoprotection.
White matter ischemia is different from gray matter in
many ways. For instance, white matter ischemia is typi-
cally more severe than gray matter because white matter
blood flow is lower than gray matter and there is little col-
lateral blood supply in deep white matter [6]. Moreover,
mechanisms responsible for ischemic cell death may be
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different between white matter and gray matter. Although
an increase in intracellular Ca2+ is involved in both white
matter and gray matter ischemia, the routes of Ca2+ entry
might differ. In white matter, pathological Ca2+ entry
occurs in part due to increased intracellular Na+ and
membrane depolarization [7-9]. Therefore, Na+ channel
blockade has been proposed as a protective strategy in
white matter [7-10]. In contrast, voltage dependent Ca2+
channels and glutamate-activated ionic receptors in gray
matter have been traditionally viewed as the primary
routes of pathological Ca2+ entry [11,12]. Of course,
beyond these differences in calcium handling, there are
potentially many other aspects of gray versus white matter
function that differ. Thus far, white matter pathophysiol-
ogy remains relatively poorly understood compared to
gray matter. Because white matter damage is a clinically
important part of stroke, we might need to take white
matter ischemia more into account to develop effective
stroke therapy.
In this mini-review, we summarize the current knowledge
on experimental systems for assessing white matter dam-
age by ischemic stress. A systematic utilization of these
cell, tissue and whole-animal platforms should enable us
to better dissect mechanisms of white matter pathophysi-
ology and help our search for oligoprotectants in stroke
and other CNS disorders.
In vitro white matter ischemia models
In pathological conditions, excitotoxic cell death is a crit-
ical part of neuronal injury, and it has been implicated in
acute injury to the CNS and in chronic neurodegenerative
disorders [13-15]. Numerous studies have now revealed
that, in addition to neurons, glial cells can also be dam-
aged by excitotoxicity. Among the glial cell types, the OLG
lineage may be the most vulnerable to excitotoxicity.
In the gray matter of the brain, neuronal cell death is often
caused by a rise of extracellular glutamate concentration,
which activates NMDA receptors and leads an excessive
rise of intracellular Ca2+ concentrations. Glutamate can
also damage white matter OLGs, in both acute and
chronic diseases [16]. Since excessive glutamate release
can be seen under brain ischemic conditions, glutamate-
induced OLG death has been used as a model for in vitro
white matter ischemia to pursue the mechanism of OLG
death by excitotoxicity. So far, there are at least three dif-
ferent mechanisms of glutamate-induced OLG death.
Using cultured OLGs prepared from new born rat brain,
Oka et al. reported that OLGs in cultures are highly vul-
nerable to glutamate. They showed that 24-h exposure of
glutamate caused OLG death by reversing cystine-gluta-
mate exchange, which induces glutathione depletion [17].
AMPA/kainate receptors have also indicated to be
involved in glutamate-induced OLG death. Sanchez-
Gomez et al. used primary cultures of OLGs derived from
the optic nerves of young-adult rat or mouse to examine
the involvement AMPA/kainite receptors in OLG death. In
the report, they revealed that excessive activation of
AMPA/kainate receptors causes Na+  and Ca2+  influx
through the receptor channel complex leading to OLG
death [18]. Until recently, it had been thought that NMDA
receptor was not involved in OLG death by excitotoxicity.
However, three recent studies have demonstrated that
OLGs also express NMDA receptors as neurons [19-21].
NMDA receptors of OLGs are activated by glutamate in
white matter ischemia [19], and activation of these recep-
tors leads to rise of intracellular Ca2+ concentration [21].
Hence, NMDA receptors might be also participate in
glutamate-induced OLG damage.
In addition to these primary excitotoxic mechanisms,
glutamate can also kill OLGs via immune-system-related
pathways. Alberdi et al. showed that brief incubation with
glutamate followed by exposure to complement is lethal
to OLGs in vitro [22]. Thus, even glutamate at non-toxic
concentrations can kill OLGs by sensitizing these cells to
complement attack. Further, inflammatory cytokines such
as TNF-alpha and IL-1beta are also known to be involved
in glutamate-induced OLG death. Those cytokines are
released by reactive microglia and can impair glutamate
uptake and trigger excitotoxic OLG death [23]. Since
glutamate is reported to release TNF-alpha from microglia
through AMPA/kainate activation, glutamate can also
induce OLG death in indirect mechanisms [24].
Although elevations in glutamate certainly occur in
stroke, alterations in other extracellular mediators may
also be important. In the CNS, extracellular ATP can act as
an excitatory neurotransmitter. ATP activates ionotropic
P2X receptor and metabotropic P2Y receptor [25,26].
Both P2X and P2Y receptors are expressed in OLGs. James
and Butt used isolated optic nerves to show that ATP
increased intracellular Ca2+  concentrations in OLGs
through P2Y receptors [27]. In addition, they also demon-
strated that a P2X receptor agonist evoked a smaller but
significant OLG Ca2+ signal. In brain ischemia and spinal
cord injury models, P2X receptors were reported to medi-
ate signaling cascades leading to neurodegeneration
[28,29]. Also in OLGs, P2X was shown to be involved in
cell death. Matute et al. have demonstrated that ATP or
P2X agonists, but not P2Y agonists, was toxic to differen-
tiated OLGs in vitro [16].
No matter what the upstream trigger might be, energetic
stress should be a common denominator for white matter
injury. In this regard, oxygen-glucose deprivation (OGD)
is a useful tool for mimicking in vitro ischemia. OGD can
induce both OPC as well as OLG death in vitro [30,31].
Indeed, it appeared that OPCs were more susceptible thanExperimental & Translational Stroke Medicine 2009, 1:6 http://www.etsmjournal.com/content/1/1/6
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OLGs [30]. More recently, using an immortalized mouse
OLG cell line, Zhang et al showed that OGD-induced
OLG death was induced by apoptosis via p75 and caspase-
3 [32]. Thus, these cell systems can be productively used
to dissect the molecular pathways of OGD-induced white
matter injury.
Compared to astrocytes, both OLGs and OPCs are rela-
tively weak. To maintain those cells in culture, a wide
spectrum of culture supplements such as growth factors
are needed. Hence, removing those factors from culture
media causes OLG or OPC death. Although this starvation
stress does not perfectly reflect in vivo ischemic condi-
tions, the stress can be thought as one of the in vitro
ischemia model and is now well used to induce OLG/OPC
damage, especially for OPC cultures. For instance, Cui et
al. reported two studies whereby IGF-1 promoted the pro-
liferation of OPCs via PI3K/Akt, MEK/ERK, and src-like
tyrosine kinase pathways [33,34]. Rubio et al. showed that
neurotrophin-3 is also important factor for OPC survival
[35]. GGF/neuregulin has been also reported to be OPC
protective [36]. Taken together, these serum deprivation
paradigms provide evidence for the essential nature of
trophic coupling for oligoprotection. Indeed, these types
of growth factor gain-and-loss experiments may help us
test drugs that can be used to salvage OPC and OLG health
in a wide range of disorders.
The experimental systems described above are all useful
for examining the mechanisms of OLG/OPC death by
ischemic stress. The main read-outs comprise either cell
survival or myelin synthesis in isolated cultures, or com-
pound action potentials in optic nerve preparations. The
ease of quantitation and the reproducibility of culture
platforms might allow for relatively high-throughput
screening. However, it must be acknowledged that in vitro
systems have some limitations. Cell and tissue systems
cannot truly replicate the inter-cellular interactions and
anatomic geometry of in vivo white matter.
In vivo rodent white matter ischemia models
White matter lesions are observed frequently in stroke
patients and experimental animal models of cerebral
ischemia, and have been thought to contribute to cogni-
tive impairment [37-39]. Since nonhuman primates have
well-developed white matter and vascular architectures
which are similar to those of human brains, it seems to be
reasonable to use them for studying the mechanisms of
white matter injury. However, from ethical and practical
standpoints, there remains an important imperative for
developing rodent models. Compared to in vitro studies
of white matter injury, basic research of white matter
injury via in vivo models is not as well developed.
Some research groups have shown that OLG damage
occur in response to ischemia in rodent middle cerebral
artery occlusion (MCAO) models. Irving et al. observed
structural changes of the OLG cytoskeleton by 40 min
occlusion of MCA [40]. They assessed these changes by
detecting increase of tau immunoreactivity within OLGs.
Tau is the microtubule associated protein, and the
increase in immunoreactivity has been found to be a sen-
sitive marker for OLG damage. The MCAO-induced OLG
damage assessed by tau immunoreactivity has been con-
firmed by other groups [41,42]. Axons and myelin struc-
ture have also shown to be damaged in rodent MCAO
models [43]. Another report by Irving et al. carefully
examined the methods of quantifying white matter injury
following prolonged focal cerebral ischemia in the rat.
This study showed that myelin basic protein, Tau 1, and
amyloid precursor protein staining can be utilized to
assess myelin and axonal integrity in rat MCAO model
[44]. Schabitz et al. have also shown the white matter
injury in rat stroke model [45]. The use of Luxol-fast blue-
periodic acid-Schiff and Bielschowsky's silver impregna-
tion allowed the detection of myelin and axons, which
could then be semi-quantified as read-outs for specific
experiments.
The two-vessel occlusion model by permanent bilateral
occlusion of the common carotid arteries has also been
used to induce white matter ischemia. This model pro-
duces chronic cerebral hypoperfusion in rat and gerbil
[46,47]. These models are characterized by pathological
changes in white matter, which appear similar to those in
human cerebrovascular white matter lesions [48,49]. As
seen in human white matter ischemia, the rat chronic cer-
ebral hypoperfusion model by the ligation of the bilateral
common carotid arteries is accompanied by cognitive
impairment [50]. In this model, however, the visual path-
way is also injured by the occlusion of the ophthalmic
arteries, and thus may affect behavioral assessment [47].
Although rats and gerbils are mostly used for these
chronic cerebral hypoperfusion models, mice have also
been used recently. With newly designed micro-coils, Shi-
bata et al. developed a new mouse model of chronic cere-
bral hypoperfusion with relative preservation of the visual
pathway [51]. In this model, white matter lesions
occurred after 14 days without any gray mater involve-
ment. Another report from Shibata et al. has demon-
strated that the mouse hypoperfusion model showed
impairment of working memory using the 8-arm radial
maze [52]. The importance of the mouse model centers
on the ability of future studies to utilize specific knock-
outs or transgenics for dissecting molecular mechanisms
and mediators. For example, the use of knockout mice for
matrix metalloproteinases (MMPs) could be anticipated.
From a biochemical basis, MMPs can directly attack mye-
lin components [53]. In fact, Nakaji et al. used the mouseExperimental & Translational Stroke Medicine 2009, 1:6 http://www.etsmjournal.com/content/1/1/6
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chronic cerebral hypoperfusion model to show that gene
knockout of MMP-2 reduced the severity of the white mat-
ter lesions [54]. Furthermore, MMP-9 knockout mice
showed the resistance to MCAO-induced degradation of
myelin-basic protein [55]. Depending on the proposed
mechanisms, the combination of specific knockout mice
with experimental induction of stroke or brain injury
should be useful for exploring the underlying mecha-
nisms involved in white matter pathophysiology.
In addition to the methods of occluding blood vessels, the
direct injection of endothelin-1 (ET-1) into the neural
parenchyma has also been used to induce white matter
ischemia [56]. ET-1 is a potent vasoconstrictor peptide,
and acts through different receptors called types A and B,
which are distributed throughout the CNS [57-59].
Hughes et al. reported that microinjection of ET-1 into the
striatum and cerebral cortex induces focal ischemia with a
reduction of 40% of local blood flow in rats [60]. The
damage in this model is localized in both gray and white
matter without blood brain barrier breakdown. Frost et al.
also used ET-1 microinjection model to induce white mat-
ter ischemia [61]. They injected ET-1 into the internal cap-
sule, and tissue necrosis and demyelination in the
infarcted white matter were found after a 14-day survival
period. Further, infarcts resulted in measurable sensorim-
otor deficits. Regarding inflammatory response in the ET-
1-injection white matter ischemia model, two studies
recently came out. They showed that inflammatory
response and white matter damage are closely related in
the rat models of ET-1 microinjection into the striatum
[62,63].
The optic nerve has been thought as one of the most use-
ful regions to study OLG functions. As cited in the previ-
ous section, numerous groups use OLG cultures from
rodent optic nerve to investigate the OLG death by
ischemia. Also in vivo system, the mechanisms of OLG
damage have been examined in optic nerve. Retinal gan-
glion cell (RGC) axons comprise the optic nerve. So far,
several in vivo models have been created to identify the
RGC response to optic nerve damage [64-67]. A recent
effort used photochemically-induced thrombosis to evoke
anterior ischemic optic neuropathy (AION) in rats and
mice [68,69]. AION may mimic optic nerve strokes, which
are among the most common causes of sudden optic
nerve-related vision loss. Discrete histopathological
changes of OLGs were reported in human AION [70].
Correspondingly, OLG dysfunction was observed in the
mouse AION model [69].
Taken together, the emergence of various mechanical,
thrombotic and chemical models now provides reasona-
ble ways to move forward in vivo. But it must be acknowl-
edged that white matter volumes in rodents are extremely
small compared to human brains. Thus, methods for
quantifying outcomes are challenging. Ultimately, com-
parisons of these rodent outcomes with human stroke
patients must be performed carefully since white matter
connectivity may be different between these vastly differ-
ing levels of brain evolution.
Remyelination in recovery phase in rodent 
stroke models
To date, the majority of studies using cell, tissue and
whole-animal models of white matter injury have mostly
focused on mechanisms and targets for acute injury. How-
ever, it may not be easy to block all multifactorial path-
ways of brain cell death in stroke patients. Therefore, an
emerging emphasis on promoting recovery after stroke is
beginning to take shape in our field. In the context of
white matter mechanisms, it will be important to carefully
define how each of the model platforms can be applied in
this regard.
To support normal brain function, neuronal connectivity
must be maintained. Hence, remyelination and regenerat-
ing axons in the border zone of cerebral infarcts and in
secondarily lesioned areas are essential for stroke recov-
ery. Fundamental research into these mechanisms of
remyelination after ischemia remains somewhat limited,
but a few studies are beginning to lead the way. Mandai et
al. reported that myelin repair can occur in peri-infarct
areas in mouse MCAO model, as judged by upregulated
gene expression of proteolipid protein, one of the major
protein components of CNS myelin [71]. Gregersen et al.
studied the expression of myelin basic protein (MBP),
another major component of CNS myelin, in peri-infarct
areas using rat MCAO model [72]. They revealed that peri-
infarct OLGs increased their expression of MBP mRNA
from 24 h to maximal levels at day 7. These changes cor-
responded to the appearance of process-bearing MBP and
occasional myelin oligodendrocyte glycoprotein-immu-
noreactive OLGs in parallel sections.
As described before, OLGs originate from their precursors;
OPCs. OPCs are now found not only during development
but pockets might also exist throughout the adult brain
[73-76]. Therefore, OPCs may contribute to myelin main-
tenance and repair by generating new OLGs as a source of
remyelination and repair. Experimental evidence is start-
ing to be collected showing that OPCs in adult brain con-
tribute to replenishment of OLGs after ischemic insults.
Tanaka et al. examined the alteration of OLGs, OPCs and
myelination in rat MCAO model [77]. They showed that
a rapid and progressive decrease in the number of OLGs,
OPCs, and myelin density after 2-day in the infarct core.
In contrast, the peri-infarct area exhibited a moderate
reduction in the number of OLGs and the myelin density
with a slight increase in OPCs at 2 days after MCAO. Sub-Experimental & Translational Stroke Medicine 2009, 1:6 http://www.etsmjournal.com/content/1/1/6
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sequently, a steady increase in the number of OPCs and a
gradual recovery of OLGs were found in the peri-infarct
area at 2 weeks of MCAO.
If OPCs provide a source of potential white matter repair,
what signals and substrates are involved? A recent interest-
ing study by Komitova et al. suggested that enriched envi-
ronments may enhance the generation of OPCs after focal
cortical ischemia. In this study, newly born OPCs were
found to be immunoreactive for brain-derived neuro-
trophic factor (BDNF) [78]. Thus, it is tempting to specu-
late that BDNF may be related to remyelination by OPC
proliferation/differentiation. What remains to be clarified
is how this signal may interact with a multitude of other
growth factors involved in OPC proliferation/differentia-
tion. Since growth factor expression is upregulated after
ischemia in peri-infarct area, a network response of
growth factors might have essential roles in remyelination
after stroke. These studies have mostly utilized in vivo
models. As we dig down deeper mechanistically, a systems
biology approach may ultimately be required as one asks
broadly what gene profiles mediate cell-cell interactions
in white matter during and after injury.
Potential therapeutic targets for white matter 
ischemia
The combined use of cell, tissue and whole-animal plat-
forms discussed here may provide powerful tools for dis-
secting the pathophysiologic mechanisms of white matter
injury in CNS disorders (see Figs. 1 and 2). Of course, no
validated drugs yet exit. But several promising leads
should be discussed.
Memantine, an uncompetitive NMDA receptor antago-
nist, has been well examined for the efficacy for prevent-
ing white matter from several insults including ischemic
stress. Memantine is now licensed for moderate-to-severe
Alzheimer's disease in US and EU [79]. Very recently, two
studies suggested that memantine may be protective to
white matter. Bakiri et al. reported that memantine
reduced ischemic damage to mature and precursor OLGs
in brain slices assessed by patch-clamp system [80]. Man-
ning et al. showed that memantine attenuated white mat-
ter injury in a rat model of periventricular leukomalacia
[81]. Therefore, NMDA receptor antagonists might be a
good target for white matter injury after stroke.
Although the radical spin-trap NXY-059 failed in clinical
stroke trial recently [82], antioxidant drugs are still potent
therapeutic candidates for white matter. Imai et al. used
rat transient ischemia models to evaluate the efficacy of
ebselen, an anti-oxidant drug [41]. In this study, they
showed that ebselen reduced axonal damage, and that
OLG pathology was also reduced. Using rat MCAO
model, Irving et al. have demonstrated that a free radical
scavenger phenyl-N-tert-butyl-nitrone (PBN) reduced the
number of tau-positive OLGs in the subcortical white
matter of the ischemic hemisphere [40]. Lin et al. also
examined the efficacy of PBN on white matter injury by
hypoxia-ischemia in the neonatal rat brain [83]. In the
study, the PBN treatment protected both OLGs and axons
from ischemic insults. Subsequently, the same group has
demonstrated that PBN also inhibited up-regulation of
inflammatory cytokines such as IL-1beta, TNF-alpha and
iNOS mRNA expression in the same model [84].
Finally, an ongoing NIH-funded trial is assessing minocy-
cline for acute stroke. Minocycline is a second-generation
tetracycline, which can cross the blood-brain barrier
[85,86]. Minocycline has been shown to be beneficial in a
Schematic for experimental systems and their endopoints Figure 1
Schematic for experimental systems and their endopoints. All systems have both advantages and disadvantages. A sys-
tematic utilization of these systems should enable us to better dissect mechanisms of white matter pathophysiology and help 
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wide range of acute neurological injuries. In rodent brain
ischemic models, this drug showed anti-inflammatory
effects, based on its ability to inhibit immune mediators
such as microglia [87,88]. Although there is no report that
minocycline directly protects OLGs against ischemic stress
in adult rodent stroke model, this drug was shown to
attenuate hypoxia/ischemia-induced white matter injury
in the neonatal rat [89,90]. Further, Hewlett and Corbett
have shown that delayed minocycline treatment reduced
long-term functional deficits as well as white matter injury
in ET-1-induced rat ischemia model [91]. In spite of these
experimental findings, it must be noted that a recent clin-
ical trail using minocycline in ALS patients failed to show
efficacy [92]. A potential caveat with this study is the long-
term use of minocycline. Among its many actions, mino-
cycline is a powerful metalloproteinase inhibitor. It has
been recently suggested that long-term suppression of
metalloproteinases may be detrimental for neurovascular
homeostasis [93]. In stroke, short term applications of
minocycline may still be possible. Ultimately, however,
whether minocycline will be useful for white matter injury
in stroke patients will have to be answered in a carefully
analyzed randomized trial.
Conclusion
OLGs, myelin-forming glial cells in the CNS, are very vul-
nerable to ischemic stress, resulting in early loss of myelin
and white matter dysfunction. Inhibiting axonal damage
and/or OLG death, and accelerating the remyelination via
OPC proliferation and differentiation may turn out to be
critical for preventing acute neuronal disconnections as
well as promoting repair and remodeling after stroke.
Although there are no clinically validated treatments to
date, several promising leads are beginning to be dissected
in experimental systems. In this mini-review, we tried to
provide a broad but brief survey of existing models at the
cell, tissue and whole-animal levels. Many studies have
productively used these model systems to dissect patho-
physiology as well as assess treatment strategies. As we
seek to cross the difficult translational hurdles between
basic science and clinical challenges, the combined use of
multiple model systems should help.
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